Akero The First To Show Fibrosis Improvement In Cirrhotic MASH

 
• By Joseph Haas
  
Liver
Akero has the first MASH drug to show a fibrosis benefit in cirrhotic patients

More from Clinical Trials

More from Therapy Areas